A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody-Mediated Interleukin-6 Inhibition in Japan
Latest Information Update: 08 Oct 2024
At a glance
- Drugs Ziltivekimab (Primary)
- Indications Cardiovascular disorders; Inflammation
- Focus Therapeutic Use
- Acronyms RESCUE-2
- Sponsors Corvidia Therapeutics; Novo Nordisk
- 29 Aug 2022 Primary endpoint has been met (The difference in the percent change in high-sensitivity C-reactive protein (hs-CRP) levels (average of all hs-CRP values prior to the administration of study drug) between each active group and placebo) , according to Results presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology
- 29 Aug 2022 Results presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology
- 26 Oct 2021 Status changed from recruiting to completed.